Recursion, Roche, and its Genentech subsidiary have unveiled a whole-genome map of specialized microglial immune cells that they plan to use toward revealing significant new targets in ...
Zero Knowledge Proof (ZKP) is built for pressure. Explore the tech and prepare for the whitelist, opening soon for early access.
TipRanks on MSN
Roche Exercises Option with Recursion Pharmaceuticals
An announcement from Recursion Pharmaceuticals ( ($RXRX) ) is now available. On October 29, 2025, Recursion Pharmaceuticals announced that Roche ...
Zacks Investment Research on MSN
Recursion Pharmaceuticals (RXRX) Stock Declines While Market Improves: Some Information for Investors
Recursion Pharmaceuticals (RXRX) closed at $5.91 in the latest trading session, marking a -6.19% move from the prior day. The stock fell short of the S&P 500, which registered a gain of 0.23% for the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback